Status:
COMPLETED
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Multiple Myeloma
Autologous Transplantation
Eligibility:
All Genders
Brief Summary
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
Detailed Description
This is a long-term observational study of patients who received at least one dose of study treatment (plerixafor or placebo) in a multicenter, randomized, double blind, placebo-controlled study to ev...
Eligibility Criteria
Inclusion
- All patients who received a dose of study treatment (plerixafor or placebo) in protocol AMD3100-3102 (NCT00103662)
Exclusion
- No Exclusion Criteria
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT00741780
Start Date
June 1 2006
End Date
July 1 2011
Last Update
March 24 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.